Discover why Japan is in focus

Why Japan

Venue: Park Hyatt Tokyo

Opportunity: Japan currently holds 11-13% of global pharma sales making it the second largest pharma market in the world

A supportive regulatory environment: with the introduction of conditional approval, companies are able to bypass costly phase 3 trials and get their product to market quicker

Reimbursement: It is predicted that 70% of the clinical trials that follow an expedited-approval pathway will be reimbursed.